>>Agreed that the INCY data aren't showing anything meaningfully different than PFE.<< Drug ACR20 minus placebo ACR20 - Incyte's primary endpoint: Pfizer: 39% Incyte: 20% That's using your data. I think we'll have to agree to disagree. My guess is that 050 will never be approved in RA. >>One has to presume PFE's first mover advantage will be a meaningful hurdle for JNJ.<< Did JNJ buy Lilly? ;o) micro